Hepatitis C virus (HCV) is a positive-strand RNA virus and a member of the Hepacivirus genus in the Flaviviridae family. Acute infection with HCV progresses into chronic infection for approximately 80% of infected patients and is a major cause of liver cirrhosis and hepatocellular carcinoma. The current use of pegylated alpha interferon (IFN-␣) in combination with ribavirin for chronic HCV infection treatment (10, 14, 16) results in a 37 to 50% sustained viral response in patients infected with HCV genotype 1 (GT-1) (15) . This suboptimal sustained viral response, combined with the high prevalence of undesirable side effects, has prompted focused efforts to develop specifically targeted antiviral therapies for HCV infections. The HCV NS5B RNA-dependent RNA polymerase (RdRp) is a critical enzyme for viral RNA replication and presents an attractive therapeutic target. Specific inhibitors for the HCV polymerase, including nucleoside analog inhibitors (7, 14, 21, 22, 30) and nonnucleoside analog inhibitors (2-6, 8, 11, 17, 18, 19, 47) , have been generated, and some have entered clinical development.
Specific nucleoside inhibitors having the 2Ј and/or 4Ј modification, including 2Ј-C-methylcytidine (NM107) (36, 37) , 2Ј-Cmethyladenosine (30) , 2Ј-C-methylguanosine (30) , 2Ј-C-methyl-7-deaza-adenosine (MK-0608) (35) , 4Ј-azidocytidine (R1479) (22) , 2Ј-deoxy-2Ј-␤-fluoro-4Ј-azidocytidine (RO-0622), and 2Ј-deoxy-2Ј-␤-hydroxy-4Ј-azidocytidine (RO-9187) (21) , have shown specific inhibition of HCV replication in vitro. Moreover, a number of these nucleoside analog inhibitors, including R1626 (prodrug of R1479) (40, 42) , NM283 (prodrug of NM107) (1) , and MK-0608 (34) , have demonstrated clinical efficacy for HCV-infected patients or for HCV-infected chimpanzees. ␤-D-2Ј-Deoxy-2Ј-fluoro-2Ј-C-methylcytidine (PSI-6130) (32, 44 ) is a potent nucleoside analog inhibitor of the HCV NS5B polymerase. R7128, a prodrug of PSI-6130, has demonstrated efficacy in a phase 1b clinical study, with a mean HCV RNA reduction of 2.7 log 10 IU/ml when administered at 1,500 mg twice daily for 2 weeks to treatment-experienced patients infected with HCV GT-1a or GT-1b (41) . In combination with poyethylene glycol-IFN/ribavirin, administration of R7128 at 1,500 mg twice daily demonstrated a decline of 5.12 log 10 IU/ml in HCV RNA levels, correlating with an 85% rapid virologic response (reduction to less than 15 IU/ml). PSI-6130 inhibits the replication of HCV through formation of its 5Ј triphosphate form, which functions as an alternative substrate for the viral polymerase, competitively inhibiting viral RNA synthesis by preventing further extension after incorporation (44) . In similarity to natural nucleotides and other nucleoside analog inhibitors, PSI-6130 undergoes uptake by the cells and phosphorylation to the 5Ј triphosphate derivative (32) . A recent study characterizing the metabolic activation of PSI-6130 in human primary hepatocytes identified a novel UTP metabolite that displayed inhibitory activity against the NS5B polymerase in vitro, indicating that PSI-6130 is metabolized into two pharmacologically active species in the cells (28) .
An early understanding of the nature of resistant HCV variants likely to emerge under conditions of drug treatment may allow improved drug design and, ultimately, the selection of inhibitors with unique resistance profiles to be used in the clinic in combination treatment regimens of greater efficacy. Nucleoside analog inhibitors with 2Ј-C-methyl modification, including 2Ј-C-methylcytidine (NM107), 2Ј-C-methyl-7Ј-deaza-adenosine (MK-0608), and 2Ј-C-methyladenosine, were shown to select for the S282T substitution in the active site of the polymerase in HCV replicon studies (23, 30, 34, 35) . Confirming the replicon study results, the S282T substitution emerged in HCV-infected chimpanzees that were treated with MK-0608 (34) . In the replicon studies, the mutation conferred a significant loss of sensitivity to these inhibitors that ranged from approximately 20-to over 100-fold, depending on the particular analog (30) . PSI-6130 has both a 2Ј-fluoro and a 2Ј-C-methyl modification on the ribose sugar moiety (Fig. 1) , thus differing from other modified nucleoside analogs which have only the 2Ј-C-methyl modification. The additional modification may alter the molecular interactions between PSI-6130 and the wild type (WT) as well as the polymerase with the S282T substitution. The S282T substitution mediated only a moderate loss of activity for PSI-6130 (32) , suggesting that PSI-6130 may have a different resistance profile compared to those of the other 2Ј-C-methyl-modified nucleoside analogs. The in vitro resistance profile emerging in the NS5B polymerase under selection with PSI-6130 has not been previously studied. Our goals were to examine the emerging amino acid substitutions following the treatment of replicon cells with PSI-6130 and to characterize the contribution of these mutations in conferring resistance to the compound.
MATERIALS AND METHODS
Compounds. PSI-6130 was synthesized at Pharmasset Inc. R7128 (a prodrug of PSI-6130), R1479 (4Ј-azidocytidine), NM107 (2Ј-C-methylcytidine), and NNI-1 (thiophene-2-carboxylic acid) ( Fig. 1) were synthesized at Roche Palo Alto LLC. Recombinant human IFN-␣-2a (Roferon) was prepared at Hoffmann-La Roche (Basel, Switzerland). PSI-6130-TP, RO2433-TP, and NM107-TP were synthesized by TriLink BioTechnologies. 3Ј-Deoxycytidine-5Ј-triphosphate (3Ј-dCTP) was purchased from TriLink BioTechnologies (San Diego, CA).
Cell lines. Cured or Lunet Huh7 cells (obtained from R. Bartenschlager) were cultured at 37°C in a humidified atmosphere with 5% CO 2 in Dulbecco's modified Eagle medium supplemented with Glutamax and 100 mg/ml sodium pyruvate. The medium was further supplemented with 10% (vol/vol) heat-inactivated fetal bovine serum and 1% (vol/vol) penicillin-streptomycin. All reagents were from Invitrogen (Carlsbad, CA).
The subgenomic replicon cell lines harboring stable WT GT-1b Con1 (2209-23) or WT GT-1a (pRLucH771b75S/I) were maintained under the same conditions as described above, with the addition of 0.5 mg/ml G418 (Geneticin; Invitrogen) (26, 43) . The replicons in these cells express the Renilla luciferase as a reporter gene. All replicon cell lines in this study were maintained at subconfluence to ensure constant levels of replicon RNA (38, 39) .
Determination of replicon inhibitory activity by use of the transient Firefly luciferase replicon, the stable Renilla replicon, and the stable qPCR assays. Assays were performed as previously described (22, 23) . Briefly, cells harboring replicons were treated with inhibitors for 72 h, and Firefly luciferase reporter signal, Renilla luciferase reporter signal, or replicon RNA levels were measured in the transient assay, the stable Renilla replicon assay, or the quantitative PCR (qPCR) assay, respectively.
The replication capacity in the transient assay was determined at 96 h following transfection, standardized to the 4-h luciferase signal following transfection, and in turn normalized against the WT replication levels. The lower limit for replication giving reliable 50% effective concentration (EC 50 ) results was determined to be at an approximate signal-to-background ratio of 10 at 96 h following transfection.
Compound cytotoxicity was determined by using the WST-1 assay as described previously (23) . Protein-adjusted shift results were determined by using the qPCR assay and cells cultured with the inhibitors in the presence of 40% (vol/ vol) human serum (Serological Corporation, Toronto, Canada) (23).
FIG. 1.
Chemical structures of HCV inhibitors used in the study. PSI-6130, ␤-D-2Ј-deoxy-2Ј-fluoro-2Ј-C-methylcytidine; R7128, PSI-6130 prodrug; RO2433, PSI-6130 uridine metabolite; NM107, 2Ј-C-methylcytidine; R1479, 4Ј-azidocytidine; NNI-1, thiophene-2 caboxylic acid.
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HCV polymerase assay. The inhibition potency of compounds with respect to the RdRp activity of recombinant NS5B570-BK, NS5B570-Con1, and NS5B570-H77 proteins was determined by measuring the incorporation of radiolabeled NMP into acid-insoluble RNA products by use of a complement strand of internal ribosomal entry site (cIRES) RNA template, as previously described (23) , with some modifications. Briefly, 50% inhibitory concentration (IC 50 ) determinations were carried out using 200 nM in vitro-transcribed cIRES RNA template, 1 Ci of tritiated UTP (42 Ci/mmol), 500 M ATP, 500 M GTP, 1 M CTP, 1ϫ TMDN buffer (40 mM Tris-HCl [pH 8.0], 4 mM MgCl 2 , 4 mM dithiothreitol, 40 mM NaCl), and 200 nM enzyme. The inhibition potency of compounds with respect to the RdRp activity of NS5B570-S282T-Con1 was determined under GT-1b assay conditions as previously described (22) . NS5B570-BK and NS5B570-Con1 enzymes were used as controls. The final reaction volume was 50 l under all assay conditions. All reactions contained a final 10% dimethyl sulfoxide. K m and K i values were measured as described previously (23) .
HCV replicase complex assay. In vitro replicase assays using purified membrane fractions from stable HCV replicon cells were performed as previously described (29) .
Compound crystallography. Suitable crystals of NM107 and PSI-6130 were obtained by evaporation of a saturated solution with methanol as the solvent. Crystals were mounted in loops and cooled to 89°K in a nitrogen stream. Diffraction data were collected using a Swiss light source (beamline X10SA) and a MAR CCD225 detector with synchrotron radiation (0.70 Å), and data were processed with XDS software. The crystal structures were solved and refined with SheIXTL (Bruker AXS, Karlsruhe, Germany).
CCDC 671178 and 675351, deposited with the Cambridge Crystallographic Data Centre, contain supplementary crystallographic data for this paper. These data can be obtained free of charge via http://www.ccdc.cam.ac.uk/cgi-bin/catreq .cgi, by emailing data_request@ccdc.cam.ac.uk, or by contacting The Cambridge Crystallographic Data Centre, 12, Union Road, Cambridge CB2 1EZ, United Kingdom (fax, 44 1223 336033).
Nucleotide sequence accession numbers. The novel NS5B sequences described in this work have been deposited in GenBank and are provided as the supplemental material. The GenBank accession numbers are FJ217353 to FJ217356.
RESULTS
PSI-6130 exhibits potent and specific inhibitory activity against HCV RNA replication mediated by the NS5B polymerase. PSI-6130 exhibits potent inhibitory activity against the replication of GT-1b subgenomic replicons (44) . In this study, the inhibitory effect of PSI-6130 was further characterized using laboratory-optimized GT-1a and GT-1b subgenomic replicons as well as a panel of replicons containing the NS5B coding region derived from GT-1a and GT-1b clinical isolates.
Using a cell line harboring a stable GT-1b (Con1 strain) subgenomic replicon expressing the Renilla luciferase and a transient (Con1) replicon system containing the Firefly reporter gene, PSI-6130 inhibited GT-1b subgenomic RNA replication with equivalent EC 50 values in both replicon systems when measured by either kinetic qPCR or luciferase reporter expression levels ( Table 1) . The prodrug R7128, developed to Table 1 ). The antiviral potency measurements obtained for the nucleoside analogs tested were independent of the method used for HCV replication quantification (quantitative reverse transcription-PCR or luciferase reporter gene quantification) and were similar when determined using stable or transient HCV replicon systems ( Table 1 ). The effect of the presence of human serum on the activity of PSI-6130 was examined. The presence of 40% human serum did not modify the inhibitory activity of PSI-6130. The mean EC 50 for PSI-6130 in the presence of 40% human serum was 0.51 M, a value equivalent to the EC 50 in the absence of human serum (Table 1) . PSI-6130 did not exhibit any cytotoxic effects on Huh-7 cells at the highest concentration tested (300 M) using the WST-1 cytotoxicity assay (Table 1) , consistent with previously reported observations (44) .
The inhibitory activity of PSI-6130 was evaluated using a panel of transient replicons containing the NS5B coding region derived from clinical isolates of treatment-naïve HCV-infected patients (Fig. 2) . The mean EC 50 values obtained for five GT-1b clinical isolates ranged from 0.60 to 1.41 M (Fig. 2) and were comparable to the values obtained for the Con1 reference strain replicon (mean EC 50 ϭ 0.51 M; Table 1 Table 1 ).
The inhibitory activity of the 5Ј triphosphate form PSI-6130 (PSI-6130-TP) against the RdRp activity of NS5B was examined by using both GT-1b (NS5B570-BK and NS5B570-Con1) and GT-1a (NS5B570-H77) recombinant enzymes ( Table 2) . PSI-6130-TP exhibited equivalent levels of potency against the BK, Con1, and H77 NS5B polymerases (Table 2) , based on IC 50 values and inhibition constants (K i ). The inhibitory activity of PSI-6130-TP in the NS5B-dependent RNA synthesis assay was comparable to the inhibitory activity of NM107-TP within assay variability limits.
Lack of emergence of replicon variants resistant to PSI-6130 in short-term in vitro selection. In this study, we sought to determine the amino acid substitutions selected in the HCV replicon system conferring resistance to PSI-6130 and the level of activity reduction mediated by those substitutions. Several initial attempts to select replicons resistant to PSI-6130 in the presence of the selection agent G418 (five independent experiments, starting with Ն5ϫ the EC 50 ) and over short-term periods (less than 4 weeks) resulted in the clearance of the replicon and an inability to generate viable cells containing resistant variants (data not shown). To enhance the possibility of obtaining resistant variants, a replicon clearance assay was employed wherein the selection process was modified by separating the treatment with the inhibitor from the selection with G418, as previously described (23) . In the first phase (the clearance phase) (Fig. 3) , the cells were incubated in the presence of 10 times the EC 50 of PSI-6130, NM107, or NNI-1 ( second phase (rebound phase), the inhibitors were removed and the cells were cultured in the presence of G418 for a period of 14 days. As controls, cells were treated separately with either NM107 or NNI-1 ( Fig. 1 and 3 ) as a nucleoside analog or as a nonnucleoside inhibitor, respectively. In the control sample treated with NNI-1, multiple colonies formed after the course of treatment ( Fig. 3 [representing the results of three experiments]). The presence of the replicon RNA in the cells was confirmed by qPCR analysis. Sequencing of the coding region for NS5B in the resulting colonies revealed the presence of the previously reported NNI-1 L419M resistance mutation (19) . In contrast to the results of the treatment with NNI-1, no viable colonies formed in the samples that were treated with PSI-6130, suggesting the clearance of the replicon from the treated cells and the lack of emergence of replication-competent resistant variants under these conditions. Similarly, no colonies emerged in the samples treated with NM107 ( Fig. 3) (23) .
Long-term selection of replicon cells with PSI-6130 and generation of replicons with reduced sensitivity to the compound. The inability to generate replicon variants resistant to PSI-6130 due to replicon clearance, as described above, prompted the use of a long-term culture approach. Cells harboring a GT-1b stable replicon were cultured over several months, with small increments in concentrations of PSI-6130 in the presence of the G418 selection reagent. In certain instances when excessive cell death occurred under conditions of selection, the concentration of PSI-6130 was reduced to encourage cell growth. Untreated replicon cells as well as cells treated with NM107 were cultured in parallel as controls. The sensitivity of the cells to PSI-6130 under conditions of selection was determined at frequent intervals, and the NS5B coding sequence was determined to examine the presence of amino acid substitutions (Table 3) .
In selection set 1 (Table 3) , the cells were cultured in the presence of PSI-6130 for a total of 53 passages. The concentration of PSI-6130 was increased gradually, starting at 2.5 M (equivalent to approximately 5ϫ the EC 50 ) and reaching 100 M at passage 53. The sensitivity to PSI-6130 was examined at several passages. At passages 6, 28, and 53, EC 50 increased 7-, 32-, and 51-fold, respectively (data representing selected passages are presented in Table 3 ). Examination of the cell population amino acid sequences of NS5B revealed that as the cells were continually passaged in the presence of PSI-6130, mutations accumulated in the polymerase. The mutations observed included Y586C at passage 6; S282T, C575S, and Y586C at passage 28; and K81R, I239L, S282T, L320F/L/C, A421V, and Y586C at passage 53 (Table 3) . Some of the mutations emerged and persisted until the end of treatment, and others were transient (e.g., C575S; Table 3 ). In contrast, no mutations were observed in the NS5B region in the cells cultured in the absence of PSI-6130 (Table 3) .
Two additional selection experiments were performed, one with PSI-6130 (set 2) and one with the prodrug R7128 (set 3) (Table 3) . Similar patterns were observed in these two selection experiments; population sequencing revealed that mutations accumulated in the NS5B coding region under conditions of PSI-6130 treatment. In selection set 2, mutations I239L, I239V, S282T, A396G, and V485L were observed. In selection set 3, mutations K72M, S282T, and L564M were detected (Table 3) . In similarity to the results seen with set 1, some mutations emerged and persisted until the end of treatment and others were transient (e.g., V485L and L564M; Table 3 ).
The S282T mutation, a substitution known to confer resis-
PSI-6130 and NM107 clear the HCV replicon. Cells harboring the stable HCV replicon were treated with 10ϫ the EC 50 of PSI-6130, NM107, or NNI-1 in the absence of G418 for 29 days (clearance phase). The inhibitors were then removed, and G418 was added for 14 days (rebound phase). HCV replicon levels were monitored using qPCR during the clearance and rebound phases. S282S/T, I239V, A396G  2  27  25  25  S282T, A396G  2  28  25  ND  S282T, I239L, A396G, V485L  2  32  25  13  S282T, I239L, A396G  3  21  30  120  K72M, S282S/T  3  26  30 tance to 2Ј-C-methyl-substituted nucleoside analogs, emerged in all three selection experiments, and it was accompanied by various other mutations. Generally, the emergence of the S282T substitution occurred after long-term passaging for more than 20 cell passages and the use of concentrations of PSI-6130 greater than 30 M. For example, in selection set 1, the S282T mutation was first observed as a mix of threonine and WT serine at passage 24 under conditions of treatment with 45 M PSI-6130 (data not shown), followed by a complete conversion to threonine at subsequent passages under conditions of treatment with 50 M PSI-6130 (Table 3) . Similar transitions were also observed in selection sets 2 and 3. After several cell passages, the cells that were treated with NM107 exhibited a reduction in sensitivity to both PSI-6130 and NM107 accompanied by the emergence of the S282T substitution without additional substitutions being observed (data not shown).
Characterization of the S282T amino acid substitution observed in the PSI-6130-selected cells. The S282T mutation was introduced into the replicon by site-directed mutagenesis and was tested in the transient replicon assay system. We observed that the S282T mutation reduced the replication capacity to 15% of the WT replication levels (Fig. 4) , in agreement with previous observations (23, 30) . We also observed that the S282T mutation conferred a moderate reduction in sensitivity to PSI-6130 and R7128. There was a three-to fourfold loss of sensitivity to PSI-6130 and R7128 compared to the results seen with WT replicons (Fig. 5A and B) . The loss of sensitivity to NM107 with this substitution was appreciably higher (22-fold) (Fig. 5C) (23) .
The effect of the S282T substitution was also examined in the context of clinical isolates. The substitution was introduced into four GT-1b clinical isolates obtained by isolating the molecular clones representing the consensus NS5B coding sequence of RO-1, RO-2, RO-3 ( Fig. 2) , or RO-11 (data not shown) and cloned into the GT-1b transient replicon. The substitution resulted in a reduction in the replication capacity (6 to 26% of that seen with the parent unsubstituted replicon) which is comparable to the reduction observed in the Con1 replicon containing the S282T substitution (15% of that seen with the parent unsubstituted Con1) ( Table 4 and Fig. 4 ). The S282T substitution also resulted in a reduction in sensitivity to PSI-6130 (3.5-to 5.4-fold) comparable to the reduction observed with the Con1 replicon (3.1-fold) ( Table 4 ; Fig. 5A ). The S282T substitution conferred a greater reduction in susceptibility to NM107, as previously observed for the S282T mutant in the GT-1b Con1 replicon (Table 4 ; Fig. 5C ).
We sought to further characterize the effects on the activity of PSI-6130, R7128, NM107, and NNI-1 mediated by the S282T substitution by using the stable HCV replicon system. The sensitivity of the HCV replicon containing the S282T substitution to PSI-6130 was examined in cells harboring the stable GT-1b HCV replicon by using the qPCR assay. The S282T substitution resulted in a moderate 2.4-fold reduction in sensitivity to PSI-6130 and a 3.4-fold reduction in sensitivity to R7128 (Table 5 ). In contrast, the S282T substitution resulted in a more pronounced reduction in sensitivity to NM107, with a 17-fold shift in the EC 50 (Table 5) . No change in sensitivity to NNI-1 was observed ( Table 5) .
The sensitivity to PSI-6130-TP and NM-107-TP of the GT-1b (Con1) recombinant NS5B enzyme containing the S282T substitution was examined using the in vitro polymerase enzymatic assay. Confirming the previously reported loss of sensitivity of the NS5B polymerase observed with the S282T mutation (32) and in agreement with the sensitivity profile observed in the replicon system, the S282T substitution resulted in a moderate reduction in NS5B sensitivity to PSI-6130-TP (5.4-fold shift in IC 50 and 2-fold shift in K i ) (Table 6) , which is in contrast to the more pronounced reduction in sensitivity to NM107-TP (111-fold shift in IC 50 and 36-fold shift in K i ) (Table 6) . Recently, an active intracellular uridine metabolite of PSI-6130, RO2433 (Fig. 1) , was identified (28, 33) . The activity of RO2433-TP was examined. The recombinant NS5B enzyme containing the S282T substitution exhibited a reduced sensitivity to RO2433-TP (20.2-fold shift in IC 50 and 21.1-fold shift in K i ) ( Table 6 ) (33) . No change in sensitivity to the control 3Ј-dCTP was found.
The effect of the S282T substitution on the activity of PSI- 6130 and NM107 was further examined by using the replicase assay. Membrane fractions containing the replicase complexes were isolated from Huh-7 cells harboring either the WT replicon or the replicon with the S282T mutation and were tested for sensitivity to PSI-6130-TP and NM107-TP. The S282T mutation resulted in a less pronounced reduction in sensitivity to PSI-6130-TP (3.1-fold shift in IC 50 ) than to NM107-TP (54.9-fold shift in IC 50 ) ( Table 7) . These results confirm the results (Table  5 and Table 6 ). No reduction in sensitivity to the control 3Ј-dCTP was observed (Table 7) . Taken together, results from this study, along with previously reported observations (32) , indicate that the S282T substitution that emerged under conditions of PSI-6130 selection only moderately reduced the activity of the compound against HCV RNA replication mediated by the NS5B polymerase.
Individual and pair-wise characterization of amino acid substitutions emerging with the S282T substitution. The amino acid substitutions that emerged and became persistently present in the three selection experiments with PSI-6130 or R7128 were tested for their effect on the replication capacity and for their effect on the sensitivity of the replicon to PSI-6130, R7128, and NM107. We characterized the K81R, K72M, I239V, I239L, L320F, A396G, A421V, C575S, and Y586C mutations (Table 3) . These amino acid substitutions were introduced as single mutations by site-directed mutagenesis into a GT-1b transient replicon containing the Firefly luciferase reporter gene. All the substitutions, except I239L, reduced the replication capacity compared to the WT replicon results (Fig.  4) . Certain substitutions had significantly lower replication capacity compared to the results seen with the WT replicon that included the A396G (1.0%) and the C575S (0.05%) substitutions. Other amino acid substitutions, including K72M, K81R, I239V, L320F, A421V, and Y586C, reduced the replication capacity to approximately 10 to 30% of WT replication levels (Fig. 4) .
The effect of the observed amino acid substitutions on the sensitivity of the replicons was examined. We observed that the levels of sensitivity of the replicons containing these mutations were comparable to those observed with the WT replicons (Fig. 5A, B, and C) . With the exception of the S282T substitution, none of the substitutions, when present alone, resulted in a noticeable change in the sensitivity to PSI-6130, R7128, or NM107.
Since the S282T substitution appeared to be the only mutation mediating a reduced sensitivity to PSI-6130, we investigated the effect of the combination of the S282T mutation in a pair-wise manner with the other observed amino acid substitutions on the replication capacity and on the sensitivity to PSI-6130, R7128, and NM107. The majority of the amino acid substitutions, when combined with the S282T mutation, caused a further reduction in the replication capacity compared to that of each substitution alone (Fig. 4) . The replication capacities of all the double mutants were less than 5% of that seen with the WT replicon. Therefore, those amino acid substitutions in this pair-wise combination pattern did not generally confer a replication advantage.
The majority of the pair-wise combinations with S282T did not significantly influence the sensitivity of the replicons to PSI-6130, R7128, or NM107 beyond the reduction observed with the S282T substitution alone (Fig. 5A, B , and C). Substitutions C575S and L320F appeared to further reduce the sensitivity to NM107 and PSI-6130, respectively, but not sensitivity to the other analogs. In addition, the I239L, A396G, and A421V mutations appeared to partially compensate for the loss of the sensitivity induced by the S282T mutation. Despite the low replication capacity seen with the replicons with the C575S, L239L/S282T, and A396G/S282T substitutions, the replication levels were above the lower limit of the assay (see Materials and Methods) and the EC 50 s obtained were reproducible.
The amino acid substitutions, either individually or in pairwise combinations with S282T, had no effect on the sensitivity of the replicons to NNI-1 (Fig. 5D) , with the exception of the A396G substitution that conferred a three-to fourfold reduction in the sensitivity to NNI-1.
Multiple combined amino acid substitutions coselected with S282T enhance replication capacity. The S282T substitution reduces the replication capacity to 15% of WT replication levels (Fig. 4) . In selection set 1 at passage 53, the NS5B coding region in those selected cells contained the S282T substitution in a complex pattern together with other mutations, including K81R, S84S/P, I239L, A300A/T, L320F/L/C, A421V, and Y586C (Table 3) . To examine the effect of having all mutations together, the NS5B coding sequence from selection set 1 at passage 53 (Table 3) was cloned into the HCV transient rep- A single clone, C5, containing only the major substitutions (including K81R, S84P, I239L, S282T, A300T, L320C, A421V, and Y586C) observed in the selected cells, was examined by transfection into Huh-7 cells and testing of replication levels as well as sensitivity to PSI-6130. When these substitutions coexisted, the replication capacity was 51% of the WT level (Fig. 4 , last column), suggesting that it was enhanced compared to the replication in replicons containing the S282T substitution alone (Fig. 4) . Furthermore, the generated replicon had a sensitivity to inhibition by PSI-6130 and NM107 (mean EC 50 s, 0.79 and 2.03 M, respectively) similar to that seen with the WT replicon (mean EC 50 s, 0.66 and 1.98 M, respectively). The nature of this change in sensitivity is not understood. The enhanced replication capacity suggests that the coemergence of a number of amino acid substitutions in a complex pattern together with the S282T adds a replication advantage to the HCV RNA by compensating for the hampered replication capacity mediated by the S282T mutation but may also be associated with reduced resistance.
Characterization of the sensitivity of the replicons generated in the selected cells. The reduced sensitivity observed in the PSI-6130-and R7128-selected cells, presented as shifts in EC 50 values (Table 3) , could be due to the emergence of resistant mutations in the replicon, to aberrant metabolism of PSI-6130 to form the active triphosphate in the cells, or to a combination of both factors. To isolate the effects attributable to changes in the replicon, whole cellular RNA was extracted from passage 32 of selection set 2 and passage 57 of the untreated cells (Table 3 ) and transfected into naïve Huh-7 cells to generate stable replicon cell lines 5R32 and RC57, respectively. The sequences of the NS5B coding region in the generated stable cells were confirmed to contain the mutations observed in the selected cells (Table 3 ). The sensitivity of the cells to PSI-6130, R7128, NM107, and NNI-1 was examined. 5R32 replicon cells exhibited a three-to fourfold reduction in sensitivity to both PSI-6130 and R7128 compared to the results seen with the RC57 control cell line (Fig. 6) . The reduction in sensitivity (55-fold shift in EC 50 ) to NM107 in these cells was more pronounced (Fig. 6) . These results suggest that the emergence of mutations in the replicon as a result of selection with PSI-6130 contributes to a low level of change (three-to fourfold) in resistance. This reduction in sensitivity corresponds to that observed with the S282T substitution in the transient assay (Fig. 5A, B, and C) .
Lack of cross-resistance between PSI-6130 and R1479. R1479 (Fig. 1) is a potent nucleoside inhibitor of HCV NS5B RdRp. R1626, the prodrug of R1479, has demonstrated a potent antiviral activity in a phase 2 clinical study (40, 42) .
As reported previously, selection of R1479 resistance replicons resulted in the identification of the NS5B mutation S96T, either alone or in combination with N142T, and the observation that this mutation was associated with R1479 resistance. Stable cell lines were generated from selection set 2 (5R32) and from untreated cells (RC57). The generated stable cell lines were tested for sensitivity to PSI-6130, NM107, and NNI-1 by the use of qPCR (error bars represent the standard errors of the means of the results of three independent experiments). The shift values were calculated based on the untreated cell line value, which was set to 1.
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S96T, alone or in combination with N142T, conferred a moderate three-to fourfold change in resistance to R1479 (23) .
In this study, we examined whether there was cross-resistance between PSI-6130 and R1479. R1479 is known to exhibit slightly enhanced potency against the S282T mutant replicon compared to WT results (Table 8 ) (23). We tested the activity of PSI-6130 against replicons containing the S96T mutation. The mutation was introduced by site-directed mutagenesis, and the effect on activity was examined by using the transient replicon assay. We observed that PSI-6130 maintained full activity against the replicon with the S96T mutation in NS5B (EC 50 of 0.42 M compared to 0.82 M for the WT) (Table 8) . Similarly, PSI-6130 also maintained full activity against the S96T/N142T double-mutant replicon (data not shown). Therefore, each of the two compounds PSI-6130 and R1479 retains antiviral activity against replicons resistant to inhibition by the other compound, indicating the lack of cross-resistance.
We next examined the feasibility of selecting replicons containing mutations conferring resistance to PSI-6130, starting with a replicon with preexisting mutations conferring resistance to R1479. Cells harboring a stable GT-1b replicon containing the S96T/N142T substitutions in NS5B that confer resistance to R1479 were treated with PSI-6130 ( Table 9 ). The concentration of PSI-6130 was increased gradually with increasing cell passage numbers, and the coding sequence of NS5B was examined periodically. Sequencing of NS5B region from the pooled population of selected cells at passages 12, 16, and 20 indicated the emergence of the S282T mutation during incubation with PSI-6130 (mixture with WT at passage 12 and full mutation at passage 16) ( Table 9) . Notably, the emergence of the S282T mutation appeared to be accompanied by a reversion of the S96T mutation back to the WT serine (Table 9) . To determine the proportions of each of the mutations in the replicon, we performed clonal sequence analysis. The NS5B coding sequences were amplified from the selected cells and then cloned into a recipient vector, and individual NS5B sequences were examined. The analysis confirmed that the emergence of the S282T substitution coincided with a reversion of the S96T substitution to the WT serine. At passage 12, the majority of the replicons contained the S282T substitution; however, it was present with a mixture of serine and threonine at position 96 (43 clones analyzed; 77% S96T and S282T, 16% S96S and S282T, 0% S96S and S282S, and 7% S96T and S282S) (Fig. 7) . The percentage of clones carrying both S282T and the revertant S96S increased at passage 16 (45 clones analyzed; 71% S96T and S282T, 29% S96S and S282T, 0% S96S and S282S, and 0% S96T and S282S) (Fig. 7) . Subsequently at passage 20, under conditions of treatment with 18 M PSI-6130, the S282T substitution was present in 100% of the clones and S96T nearly fully reverted to S96S (21 clones analyzed; 10% S96T and S282T, 90% S96S and S282T, 0% S96S and S282S, and 0% S96T and S282S) (Fig. 7) . No change was observed for the N142T substitution under the incubation conditions, and the mutation persisted until the end of the selection. This is in agreement with previous observations that the N142T substitution alone does not decrease the replication capacity and the sensitivity to R1479 (23) .
The sensitivity of the replicon cells selected with PSI-6130 was examined using the qPCR assay. Replicon cell samples from passage 20 were treated with NNI-1, PSI-6130, R7128, or NM107 and compared to untreated control cells (Table 10 ). The treatment with PSI-6130 resulted in a reduction in the sensitivity to the PSI-6130 compound, to the prodrug R7128, and to NM107 (change from 0.73 M to 5.1 M for PSI-6130, from 0.58 M to 3.2 M for R7128, and from 0.69 M to 36.5 M for NM107) ( Table 10 ). The loss of sensitivity was as predicted, mainly due to the emergence of the S282T mutation (Table 9 and Fig. 7) , although, as was observed previously (Table 3) , cellular-factor-mediated resistance (cellular factors affecting the formation of the active triphosphate metabolites) may also have contributed to the overall observed loss of sensitivity. The sensitivity of the cells to R1479 increased (change from 15.9 M to 2.13 M; Table 10 ), which corresponded to the reversion of the S96T mutation to WT (Table 9 and Fig. 7) . No change in sensitivity was observed for the control NNI-1 (Table 10) .
When present alone, the S96T or the S282T mutation significantly reduces the replication capacity of the replicon (4% or 15% of WT, respectively; Table 8 ) (23) . To examine the effect of the combination of the two mutations when present in the same replicon, we generated replicons containing both mutations by site-directed mutagenesis and the replication capacity was examined by using the transient replicon assay. When combined, the S96T and the S282T mutations caused a drastic reduction in the replication capacity to 0.6% of WT (Table 8) , indicating low viability for such replicons. The NS5B/S96T substitution reduces the sensitivity of the replicon to R1479 (Table 8 ) (23); however, the mutation did not reduce the sensitivity to PSI-6130 (EC 50 of 0.42 M compared to 0.82 M for WT) (Table 8) , suggesting the lack of cross-resistance. The sensitivity of replicons containing the combination of both S96T and S282T could not be determined due to the low replication capacity of the replicon (Table 8) .
Therefore, treatment with PSI-6130 generates the predicted resistance mutation and reverts the preexisting resistance mutation for R1479 to WT, suggesting that the two compounds possess nonoverlapping, mutually exclusive mutations, likely due to the low replication capacity of the double-mutant S96T/ S282T replicon.
DISCUSSION
PSI-6130 exhibited potent activity when examined with laboratory-optimized GT-1a and GT-1b stable and transient HCV replicons, as well as with the respective NS5B enzymes. The inhibitor also consistently demonstrated potent activity against replicons expressing GT-1a or GT-1b NS5B obtained from clinical isolates.
The HCV replicon system has been useful in predicting the emergence of resistant mutations in patients treated with polymerase or protease HCV inhibitors, for example, HCV-796 (46) or telaprevir (13, 20) , respectively. We used the in vitro HCV replicon system in this study to identify the mutations that emerge under conditions of treatment with PSI-6130 and that confer reduced sensitivity to the compound. To date, no evidence of the presence of the S282T mutation has emerged in studies of patients exposed to monotherapy with R7128 for 14 days (25) .
One explanation for the lack of detection of resistance mutations in the clinic to date is the apparent high barrier to the generation of resistance to PSI-6130, most probably due to the low replication fitness combined with only a low level of resistance gained from the mutant virus. A short-term (less than 4 week) direct selection method that has been used successfully to obtain resistant variants in vitro for other inhibitors (23, 24, 27, 31, 45) did not generate variants resistant to PSI-6130. In the replicon clearance assay, treatment of the cells with 10ϫ the EC 50 of PSI-6130 for 29 days resulted in the clearance of the replicon from the cells. This feature also seems to be shared with NM107 and R1479, which also cleared the replicon during the clearance process (23) This was in contrast to the results seen with treatment with NNI-1. Resistant variants containing the previously described L419M substitution (19) readily emerged under conditions of drug treatment. This suggests that the barrier to resistance to PSI-6130 and NM107 is higher than that to resistance to NNI-1.
Long-term culturing of the cells, accompanied by incremental increases in PSI-6130 concentrations, was required to obtain variants conferring reduced sensitivity to PSI-6130. Several months of culturing of the cells in the presence of PSI-6130 generated variants with reduced sensitivity to PSI-6130. This provides further evidence for a high barrier to the generation of variants resistant to PSI-6130 in vitro.
The higher hurdle to the generation of resistance to PSI-6130 may be explained by the fact that the S282T substitution causes only a moderate loss of sensitivity to PSI-6130, as demonstrated in the enzymatic assays and the replicon assays using laboratory-optimized as well as clinical isolate-derived replicons. However, the substitution also caused a drastic 85% loss of replication capacity when tested in the transient replicon system (Fig. 4) (23) .
In the three selection sets, two using PSI-6130 and one using the R7128 prodrug, the S282T was the only substitution commonly selected in all three experiments; however, several other substitutions emerged along with the S282T substitution. The three sets were selected under identical conditions, but the coemerging mutations appeared to differ. The difference in coemerging substitutions is not predicted to be due to the difference between PSI-6130 and the prodrug R7128, as they are both known to convert to the same active species (28) . We hypothesize that the seemingly higher level of resistance observed for the cells selected with the prodrug R7128 (120-fold) compared to the levels seen with cells selected with PSI-6130 (30-to 50-fold) is due to cellular effects on the metabolisms of both the drug and the prodrug to form the active triphosphate species. The effects attributed to the replicon itself were determined through retransfection of RNA from the selected cells into naïve Huh-7 cells and generation of stable cell lines. The resulting stable replicon cells showed only a low level of resistance (three-to fivefold), a level that is comparable to the resistance observed with the S282T substitution alone. Therefore, the different apparent resistance level in the original selected cells is not due to the replicon but rather to the host cells. Although the phenomenon of selecting host cells with a modified nucleoside metabolism may be specific to the tissue culture experimentation, it suggests that, in the clinic, individual differences in the metabolism of the nucleoside inhibitor are likely to play a role in determining the virological response to the treatment.
The reduced replication capacity appears to be rescued by the generation of other mutations in NS5B, thus providing a plausible explanation for the length of time required to gen-erate variants with reduced sensitivity to PSI-6130. In the selection studies, a number of amino acid substitutions emerged under conditions of PSI-6130 treatment (Table 3 ). The presence of the other coselected mutations appeared to enhance the replication capacity. The replicon containing the mutations observed in selection set 1 at passage 53 (Table 3) had an replication capacity (51% of WT) that was improved in comparison to the replication capacity of the S282T mutant alone, which exhibited only a 15% replication capacity. Also, stable cell lines generated by the transfection of RNA from the PSI-6130-selected cells (for example, 5R32 of set 2) (Fig. 6 and data not shown) had an improved replication capacity based on replicon levels in the cells (range, 50 to 82% of the WT levels). These results suggest that the presence of the coselected mutations in NS5B in a complex combination pattern can compensate for the reduced replication capacity caused by the S282T mutation. It is possible that substitutions outside of the NS5B region (not analyzed in this study) could also contribute to the replication advantage. Further investigation is required to discern the exact combination of mutations required for the improved replication capacity.
PSI-6130 appears to possess a more favorable activity profile with respect to the NS5B polymerase containing the S282T substitution compared to other 2Ј-C-methyl-modified polymerase inhibitors. The reduction in sensitivity to PSI-6130 with the S282T substitution was moderate (range, two-to sixfold loss of activity). In contrast, the reduction of sensitivity to NM107 (range, 17-to 50-fold loss of activity) and to 2Ј-C-methyladenosine (range, 18-to 100-fold loss of activity) (30) was more pronounced. RO2433-TP is the active uridine metabolite for PSI-6130, which has 20-fold loss of inhibitory activity with S282T mutation polymerase. This activity and resistance profile suggests that this metabolite may also contribute to the emergence of the S282T substitution.
The reason for the higher activity of PSI-6130 against the NS5B polymerase containing the S282T substitution compared to that seen with other 2Ј-C-methyl-substituted nucleoside inhibitors is unclear. Molecular modeling suggested that the change from serine to threonine at position 282 causes a steric clash between the methyl group of the NM107 and the methyl group of the threonine, hence causing a significant loss in the affinity to NM107 (12) . Shifts in K i values indicated a more moderate loss of affinity to PSI-6130 than that seen with NM107 (Table 6 ). One possible explanation is that PSI-6130 may adopt a conformation that alleviates the steric hindrance, allowing more favorable interactions with the mutant polymerase. Alternatively, the weakening of the hydrogen bonding interaction between D225 and the ribose 2Ј-hydroxyl group by fluorine substitution may increase ribose structural flexibility in the NS5B active site, allowing PSI-6130 to avoid the S282T steric clash. In support of this hypothesis, it was recently shown that the capability of a hydrogen bonding interaction with D225 was not required for potent inhibition of HCV replication by nucleoside analogs (21) . PSI-6130 is known to adopt the 3Ј-end conformation in the solid state (9, 12) . We determined the crystal structures of NM107 and PSI-6130 (Fig. 8 ) and observed that both inhibitors adopt the 3Ј-end conformation at the ribose sugar moiety. However, many nucleosides differ in conformation in the solution phase from the solid state. For example, AZT is known to adopt the C-2Ј-endo conformation in the crystal state but exists as a 1:1 mixture of C-2Ј-endo and C-3Ј-endo in the solution phase. Therefore, it is possible that differences observed in the potency of NM107 and PSI-6130 against the S282T mutant might be due to differences in the conformations of these two structures in the solution phase.
PSI-6130 and R1479 select for different resistance mutations (S282T and S96T/N142T, respectively). When tested for crossresistance, each of those two inhibitors did not lose activity against the resistant mutants of the other compound, indicating the lack of cross-resistance. In addition, we also observed that in replicon cells containing the S96T substitution, treatment with PSI-6130 induced a reversion of the S96T mutation to the WT serine accompanied by the emergence of the S282T substitution. The pressure for mutation reversion could be explained by the fact that the combination of the S96T and S282T mutations causes a dramatic reduction in the replication capacity, from 4% of WT for the S96T mutation and 15% for the S282T mutation to 0.6% for the combination of the two mutations. The incompatibility of the two mutations when present in the replicon offers a clinical advantage for a potential combination therapy. Viruses simultaneously resistant to both inhibitors under conditions of combined drug treatment are predicted to have severely reduced replication fitness.
The results from this study demonstrate that the generation of variants resistant to PSI-6130 in vitro requires long-term passage. The emergence of the S282T mutation, which mediates only a moderate three-to sixfold reduction in sensitivity to PSI-6130, is accompanied by a number of coselected mutations that appear to enhance the replication capacity. This indicates a high hurdle to the generation of mutations conferring reduced sensitivity to PSI-6130 in vitro. The clinical relevance and the potential benefit are yet to be demonstrated in the ongoing R7128 clinical trial, which is designed to observe the clinical response to the drug and the emerging resistance profile. Finally, PSI-6130 and R1479 lack cross-resistance, and the simultaneous presence of mutations resistant to both compounds drastically reduces the replication capacity, offering a promising potential for a future combination therapy.
